Exploration of the efficacy and prognostic factors of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in the treatment of metachronous peritoneal metastasis from colorectal cancer
Exploration of the efficacy and prognostic factors of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in the treatment of metachronous peritoneal metastasis from colorectal cancer
Objective To observe the effect of cytoreductive surgery(CRS)combined with hyperthermic intraperitoneal chemotherapy(HIPEC)in the treatment of metachronous peritoneal metastasis from colorectal cancer,and to analyze the prognostic factors of patients.Methods 78 patients with metachronous peritoneal metastasis from colorectal cancer were treated with CRS combined with HIPEC.Kaplan-Meier method was used to analyze the survival of 78 patients.The survival time of patients with different clinical data was compared,and Cox regression model was used to analyze the prognostic factors.Results 78 patients were followed up for a minimum of 2.9 months to the longest of 61.4 months.The median survival time was 22.1 months,and the survival rates of 12,24,36 and 60 months were 78.1%,49.0%,20.9%and 5.4%,respectively.Univariate analysis showed that age≥60 years,primary tumor located in the rectum,peritoneal cancer index(PCI)score≥12 points,tumor cell reduction(CC)score of 2～3 points,and postoperative complications of grade 3～4 were associated with the survival time of patients.Multivariate analysis showed that primary tumor located in the rectum,PCI score≥12 points,and CC score of 2～3 points were independent prognostic factors affecting the survival time of patients with metachronous peritoneal metastasis from colorectal cancer after CRS combined with HIPEC treatment.Conclusion CRS combined with HIPEC treatment can prolong the survival time of patients with metachronous peritoneal metastasis from colorectal cancer.The primary tumor located in the rectum,PCI score≥12 points,and CC score of 2～3 points are independent prognostic factors affecting the prognosis of such patients.Strict control of indications and complete CRS are the keys to benefit patients.
维普
万方数据